Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.

[1]  A. Hazekamp,et al.  An Overview of Galenic Preparation Methods for Medicinal Cannabis , 2019, Current Bioactive Compounds.

[2]  P. Morales,et al.  Cannabinoid Ligands Targeting TRP Channels , 2019, Front. Mol. Neurosci..

[3]  J. Szaflarski,et al.  Cannabis for the Treatment of Epilepsy: an Update , 2018, Current Neurology and Neuroscience Reports.

[4]  J. Maroon,et al.  Review of the neurological benefits of phytocannabinoids , 2018, Surgical neurology international.

[5]  R. Budriesi,et al.  Castanea sativa Mill. Bark Extract Protects U‐373 MG Cells and Rat Brain Slices Against Ischemia and Reperfusion Injury , 2017, Journal of cellular biochemistry.

[6]  G. Appendino,et al.  Phytocannabinoids: a unified critical inventory. , 2016, Natural product reports.

[7]  M. Wallace,et al.  Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence , 2015, Current Pain and Headache Reports.

[8]  S. Dey,et al.  Endocannabinoid signaling at the periphery: 50 years after THC. , 2015, Trends in pharmacological sciences.

[9]  R. Mechoulam,et al.  Early phytocannabinoid chemistry to endocannabinoids and beyond , 2014, Nature Reviews Neuroscience.

[10]  M. Cascio,et al.  Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. , 2014, Bioorganic & medicinal chemistry.

[11]  L. Premkumar.  Transient Receptor Potential Channels as Targets for Phytochemicals , 2014, ACS chemical neuroscience.

[12]  M. Maccarrone,et al.  Physical activity and the endocannabinoid system: an overview , 2014, Cellular and Molecular Life Sciences.

[13]  Robert M. Jones,et al.  Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. , 2013, Journal of medicinal chemistry.

[14]  Rizi Ai,et al.  Ligand-specific homology modeling of human cannabinoid (CB1) receptor. , 2012, Journal of molecular graphics & modelling.

[15]  P. Ganji,et al.  Deoxygenation of hydroquinones as a general route to norbornane-fused aromatic systems: an entry into substituted and functionalized dimethano- and methanoanthracenes. , 2012, The Journal of organic chemistry.

[16]  M. Frosini,et al.  Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor. , 2011, Journal of medicinal chemistry.

[17]  K. Bley,et al.  Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch , 2011, British journal of anaesthesia.

[18]  M. Frosini,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. , 2011, Journal of medicinal chemistry.

[19]  S. Hecht,et al.  Design, synthesis, and evaluation of an α-tocopherol analogue as a mitochondrial antioxidant. , 2010, Bioorganic & medicinal chemistry.

[20]  E. Hermans,et al.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. , 2010, Biochemical pharmacology.

[21]  C. Fiorentini,et al.  The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating μ-opioid receptors , 2009, PAIN®.

[22]  Federico Corelli,et al.  New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. , 2009, Journal of medicinal chemistry.

[23]  L. Petrocellis,et al.  An introduction to the endocannabinoid system: from the early to the latest concepts , 2009 .

[24]  B. Roufogalis,et al.  ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1 , 2008, Current neuropharmacology.

[25]  T. Bisogno,et al.  Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. , 2007, Bioorganic & medicinal chemistry.

[26]  T. Bisogno,et al.  In vitro and in vivo pharmacology of synthetic olivetol‐ or resorcinol‐derived cannabinoid receptor ligands , 2006, British journal of pharmacology.

[27]  M. Barnes.  Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain , 2006, Expert opinion on pharmacotherapy.

[28]  A. Makriyannis,et al.  Natural cannabinoids: templates for drug discovery. , 2005, Life sciences.

[29]  R. Pertwee,et al.  Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.

[30]  T. Bisogno,et al.  Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. , 2005, Journal of medicinal chemistry.

[31]  D. Lynch,et al.  N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. , 2002, Molecular pharmacology.

[32]  R. Razdan,et al.  Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[33]  C. Bonechi,et al.  Conformational analysis of N‐arachidonylethanolamide (anandamide) using nuclear magnetic resonance and theoretical calculations , 2001 .

[34]  S. Yu,et al.  3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. , 1999, Bioorganic & medicinal chemistry.

[35]  R. Pertwee,et al.  Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.

[36]  D. Kendall,et al.  Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1 , 1998, Journal of neurochemistry.

[37]  D. R. Compton,et al.  Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. , 1996, Journal of medicinal chemistry.

[38]  T. Bonner,et al.  A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. , 1996, Molecular pharmacology.

[39]  K. Metters,et al.  Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors , 1996 .

[40]  L. De Petrocellis,et al.  Assay of TRPV1 Receptor Signaling. , 2016, Methods in molecular biology.